Immunotherapeutic nanoparticles: From autoimmune disease control to the development of vaccines

Romina Mitarotonda, Exequiel Giorgi, Tatiane Eufrasio-da-Silva, Alireza Dolatshahi-Pirouz, Yogendra Kumar Mishra, Ali Khademhosseini, Martin F. Desimone*, Mauricio De Marzi, Gorka Orive

*Corresponding author for this work

Research output: Contribution to journalReviewpeer-review

Abstract

The development of nanoparticles (NPs) with potential therapeutic uses represents an area of vast interest in the scientific community during the last years. Recently, the pandemic caused by COVID-19 motivated a race for vaccines creation to overcome the crisis generated. This is a good demonstration that nanotechnology will most likely be the basis of future immunotherapy. Moreover, the number of publications based on nanosystems has significantly increased in recent years and it is expected that most of these developments can go on to experimentation in clinical stages soon. The therapeutic use of NPs to combat different diseases such as cancer, allergies or autoimmune diseases will depend on their characteristics, their targets, and the transported molecules. This review presents an in-depth analysis of recent advances that have been developed in order to obtain novel nanoparticulate based tools for the treatment of allergies, autoimmune diseases and for their use in vaccines. Moreover, it is highlighted that by providing targeted delivery an increase in the potential of vaccines to induce an immune response is expected in the future. Definitively, the here gathered analysis is a good demonstration that nanotechnology will be the basis of future immunotherapy.

Original languageEnglish
Article number212726
JournalBiomaterials Advances
Volume135
Number of pages21
DOIs
Publication statusPublished - 2022

Keywords

  • Allergy
  • Autoimmune disease
  • Immune stimulation
  • Immunomodulation therapy
  • Immunosuppressants
  • Nanoparticles

Fingerprint

Dive into the research topics of 'Immunotherapeutic nanoparticles: From autoimmune disease control to the development of vaccines'. Together they form a unique fingerprint.

Cite this